Nuvectis Pharma announces common stock offering, no amount given

Nuvectis Pharma (NVCT) announced that it has commenced an underwritten public offering of its common stock. All of the shares to be sold in the offering will be offered by Nuvectis. Nuvectis intends to use the net proceeds from this offering to continue to advance the development programs of NXP800 and NXP900 or any future product candidate, hiring of additional personnel, capital expenditures, costs of operating as a public company and other general corporate purposes. Lucid Capital Markets is acting as sole book runner for the offering.